CN115212338A - 一种聚己内酯-黄原胶-黄连素复合生物膜及其制备方法与应用 - Google Patents
一种聚己内酯-黄原胶-黄连素复合生物膜及其制备方法与应用 Download PDFInfo
- Publication number
- CN115212338A CN115212338A CN202210815912.9A CN202210815912A CN115212338A CN 115212338 A CN115212338 A CN 115212338A CN 202210815912 A CN202210815912 A CN 202210815912A CN 115212338 A CN115212338 A CN 115212338A
- Authority
- CN
- China
- Prior art keywords
- polycaprolactone
- xanthan gum
- berberine
- solution
- composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001285 xanthan gum Polymers 0.000 title claims abstract description 118
- 229940093265 berberine Drugs 0.000 title claims abstract description 110
- 239000002131 composite material Substances 0.000 title claims abstract description 58
- 239000012528 membrane Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000000230 xanthan gum Substances 0.000 claims abstract description 76
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 76
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 74
- 235000013305 food Nutrition 0.000 claims abstract description 6
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 68
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 68
- 239000004632 polycaprolactone Substances 0.000 claims description 65
- 229920001610 polycaprolactone Polymers 0.000 claims description 65
- 238000009987 spinning Methods 0.000 claims description 33
- 239000002121 nanofiber Substances 0.000 claims description 26
- 238000010041 electrostatic spinning Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 239000000835 fiber Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 238000007872 degassing Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229960000583 acetic acid Drugs 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 239000012362 glacial acetic acid Substances 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims 1
- 238000009512 pharmaceutical packaging Methods 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 33
- 239000000463 material Substances 0.000 abstract description 30
- 239000003814 drug Substances 0.000 abstract description 6
- 238000004806 packaging method and process Methods 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000000419 plant extract Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 40
- 239000010408 film Substances 0.000 description 28
- 241000588724 Escherichia coli Species 0.000 description 13
- 230000006870 function Effects 0.000 description 12
- 244000063299 Bacillus subtilis Species 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 235000014469 Bacillus subtilis Nutrition 0.000 description 10
- 206010052428 Wound Diseases 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000010907 mechanical stirring Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 5
- 238000000576 coating method Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229920005615 natural polymer Polymers 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000004753 textile Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010022355 Fibroins Proteins 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002048 multi walled nanotube Substances 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000011206 ternary composite Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001313855 Bletilla Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 241000218202 Coptis Species 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 229920000704 biodegradable plastic Polymers 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000002884 effect on inflammation Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 230000005686 electrostatic field Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940059442 hemicellulase Drugs 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229930013397 isoquinoline alkaloid Natural products 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D65/00—Wrappers or flexible covers; Packaging materials of special type or form
- B65D65/38—Packaging materials of special type or form
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/70—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres
- D04H1/72—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged
- D04H1/728—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/208—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2565/00—Wrappers or flexible covers; Packaging materials of special type or form
- B65D2565/38—Packaging materials of special type or form
- B65D2565/381—Details of packaging materials of special type or form
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Textile Engineering (AREA)
- Mechanical Engineering (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种聚己内酯‑黄原胶‑黄连素复合生物膜及其制备方法与应用,该制备方法为将黄连素、黄原胶和聚己内酯通过静电纺丝技术制备成复合纳米纤维膜。本发明制备的聚己内酯‑黄原胶‑黄连素复合生物膜,其操作简单,成本较低,制得的薄膜材料规整性好,可降解,具有一定的抗菌功能。本发明制备方法将天然药用植物提取液复合到基体中,经黄原胶改性后的薄膜均匀,韧性和延展性好,可生物降解性,生物相容性好,抗菌作用增强。可以广泛应用于医用敷料、组织工程和医药食品包装等领域。
Description
技术领域
本发明属于复合薄膜材料技术领域,具体涉及到一种聚己内酯-黄原胶-黄连素复合生物膜及其制备方法与应用。
背景技术
在人体创伤愈合过程中,医用敷料能起到保护创面、吸附渗出、防止感染、清除坏死组织等作用。目前,我国绝大多数医疗机构仍将棉质纱布、绷带等作为常用的医用敷料,但传统医用敷料易与伤口粘连、保湿性能差,且需经常更换,难以满足慢性伤口护理的需求。医用敷料理想情况下应具备以下特点:使用方便、致敏性低、成本适中;保持创面的湿润环境;隔离外部污染、清除坏死组织、吸收渗出液;无毒无害与人体相容性良好。
近年来,纳米纤维材料具有极高的比表面积及孔隙率等优异性能,在生物医用领域被广泛研究,但单一成分的纳米纤维在结构性能上或多或少存在局限,并不能完全满足材料的各种需求,因此研究人员通过对不同来源的材料和纳米纤维进行复合,以实现材料的功能化和综合性能的最优化,拓宽其应用领域。以可生物降解的复合材料(胶原蛋白、壳聚糖、聚己内酯、白及胶、黄原胶、聚乳酸等)为原料经静电纺丝制备的新型医用敷料,对于传统敷料的替代以及理想敷料的开发和研究具有重要意义。
聚己内酯(ε-caprolactone,PCL)是一种常用生物可降解高分子聚合材料,具有很高的强度和良好弹性等力学性能,熔点(60℃)和玻璃化转变温度(-60℃)低,易与其他聚合物结合使用。这种材料具有良好的柔韧性、加工性、生物相容性、降解性、疏水性和药物通性,在生物医用材料领域广泛应用于血管、肌腱、软骨、骨等生物医学材料领域。在体内PCL酯键水解后,长链断裂,形成小碎片,最终被机体代谢吸收。研究发现,PCL进入人体后短时间内有轻微炎症反应,随后消失,且PCL对免疫细胞活性影响不大,因此PCL是生物相容性材料。橡胶态的PCL虽然柔韧性大,生物相容性强,但生物降解速率缓慢,PCL的蜡质感和脆性导致成膜困难,这限制了PCL在很多领域的应用。因此,将具有良好生物相容性和具有功能性的其他材料和PCL材料共混,可实现优势的互补,得到力学性能较好的复合材料。例如:聚己内酯与改性玉米淀粉制备的复合膜,不仅可以降低双改性淀粉的结晶度和玻璃化温度,改善淀粉的机械加工性能,而且淀粉/PCL热塑性完全生物降解塑料膜的物理性能和力学性能较为优良,120d内土埋生物降解失重率达70%以上。聚己内醋/聚乙烯醇(甲硝哩)纳米纤维膜、聚己内酯/壳聚糖/二甲双胍纳米纤维膜等具有良好的释药功能,而小鼠胚胎成纤维细胞(NIH-3T3)能够在聚乳酸-聚己内酯/丝素蛋白三元复合纳米纤维膜上生长良好,在组织工程作为生物支架具有广阔的应用前景。聚乙烯醇/海藻酸钠/黄连素医用敷料对大肠杆菌和金黄色葡萄球菌的抑菌率分别高达99.41%、97.89%。但是聚己内酯疏水性高、降解速度慢,使其生物相容性较差,限制了其应用。
黄原胶又称黄胶、汉生胶,为白色或淡黄色粉末。具有类似纤维素的一级结构,包括由β-1,4键连接的D-葡萄糖基主链以及含三个糖单位的侧链,侧链由两个D-甘露糖和一个D-葡萄糖醛酸交替连接而成。黄原胶分子中含有-COO-、-OH等强极性基团,带电荷的侧链反向缠绕在主链上,有序状态时主链与侧链靠氢键作用形成双螺旋结构,这些螺旋结构以静电力和空间位阻效应等来保持其稳定。黄原胶复杂的聚集态结构和较强的分子间作用力决定了其溶液了其水溶液具有良好的增粘、流变、抗盐和抗剪切等性能,并对酶解也具有良好的稳定性。研究发现к型-卡拉胶(к-CA)和黄原胶(XG)复合水凝胶其装载左氧氟沙星具有很好的抗菌性能。以聚偏氟乙烯(PVDF)为原料,氧化石墨烯(GO)和多壁碳纳米管(MWCNTs)为添加剂,黄原胶(XG)作为凝胶浴,通过非溶剂相转化(NIPS)法制备改性膜具有较好的抗污染性能。黄原胶自是世界上应用最为广泛的生物胶之一,还是目前既具有药物活性成分又可生物降解、性能最优越的生物胶。在食品、石油、医药领域都有所应用。然而单一的黄原胶其力学性能和抗菌性能不足,不能较好地支撑创面以及抑制创面感染菌滋生。
黄连素(Berberine,BR)又名小檗碱,为异喹啉类生物碱,是从毛莨科黄连属植物黄连的根状茎中提取的主要有效成分。黄连素分为分子型和离子型两种,其结构中的季铵氮作为碱性中心,可以形成盐酸盐和硫酸盐两种。黄连素可以抑制或杀灭多种革兰染色阳性及阴性菌、结核杆菌和真菌。此外黄连素对炎症疗效明显,因为其可对某些炎性细胞和炎性介质起作用;可增强非特异性免疫功能,抑制特异性免疫作用;抑制中性粒细胞的趋化作用;抑制中性粒细胞磷脂酶A2(PLA2)的活性;降低急性炎症组织中PGE2含量;通过抗血小板凝聚功能发挥抗炎作用。黄连素是一种具有广谱抗菌、药源广泛、价格低廉,应用历史悠久、不易产生耐药性,还可提高机体免疫力的抗菌添加剂。
静电纺丝被认为是最有效的纳米纤维生产技术。静电纺丝时,聚合物溶液被注射泵送到毛细管口,在高压静电场的作用下,克服表面张力形成射流,在行进的过程中溶剂挥发形成纳米纤维,最终沉积在接收装置上。通过调节静电纺丝的条件,如聚合物溶液的浓度、施加的电压、灌注速度、环境温湿度、接收装置和距离等可调节纤维的直径和形貌,从而获得满足不同需求的纤维结构。例如,静态平板或滚筒可分别收集随机排列或有同一取向的纤维。细胞外基质(ECM)的主要蛋白质是胶原蛋白,表现为直径50-500nm的纳米纤维,并通过其结构控制细胞行为。因此,静电纺丝制备的纳米纤维膜具有模拟ECM的独特的结构特点,能促进细胞的粘附和迁移。此外,静电纺丝纳米纤维膜的高比表面积和孔隙率有利于体内氧气-液体的交换,被认为是理想的组织工程材料之一。
单一组分的生物材料难以同时具备良好的物理、化学和生物等性能,将多种物质组合制备出复合纳米纤维膜或者在纳米纤维表面膜进行功能修饰成为近年来的研究热点。
发明内容
本发明的目的是提供一种聚己内酯-黄原胶-黄连素复合生物膜及其制备方法与应用,可以在增强黄原胶和聚己内酯各自优势以改善成膜可控性和机械性能的同时,保持良好的抗菌性能和生物活性,扩展了复合材料在生物医学领域的可应用范围。
为达上述目的,本发明提供了一种聚己内酯-黄原胶-黄连素复合生物膜的制备方法,包括以下步骤:
将聚己内酯溶液与黄原胶溶液混合均匀后,超声脱气并加入黄连素,搅拌并超声脱气后,制得聚己内酯-黄原胶-黄连素纺丝液;
将纺丝液注入注射器中,调解纺丝参数为:电压15kV、距离20cm、进样速率为1mL/h,经静电纺丝技术制得聚合物溶液后,制备纳米纤维膜;
静电纺丝的纺丝温度为17~23℃,静电纺丝的相对湿度为55~65%,静电纺丝的时间为24~48h。
本发明中选用聚己内酯/黄原胶为载体,添加黄连素,通过静电纺丝技术制备一种可生物降解的复合生物膜,由于聚己内酯的疏水性高、降解速度慢,使其生物相容性较差,限制了其应用;而黄原胶水溶液稳定性较高,具有良好的增粘、流变、抗盐和抗剪切等性能,并对酶解也具有良好的稳定性,许多酶如蛋白酶、淀粉酶、纤维素酶和半纤维素酶等都不能使黄原胶降。二者合用能够弥补聚己内酯疏水性较强的缺点,并且将两种材料的优点结合起来。
从组分上看,本发明采用天然聚合物通过静电纺丝技术制备医用纳米复合生物膜,天然聚合物因其生物相容性、生物降解性、高仿生水平和物理化学性质而被广泛应用于医用敷料、组织工程和医药食品包装等领域。特别是基于天然聚合物的医用敷料,其降解速率可以与伤口愈合过程同步,确保了活性物质的有效释放,避免了伤口的二次伤害。该复合膜由于黄原胶和黄连素的协同抗菌作用,大大增强了抗菌效果。
进一步地,聚己内酯溶液由聚己内酯溶解于冰醋酸溶液中制得,聚己内酯溶液中聚己内酯的质量分数为8~12wt%。
进一步地,黄原胶溶液由黄原胶溶解于去离子水中制得,黄原胶溶液中黄原胶的浓度为0.15~0.18g/mL,溶解的温度为75~85℃。
进一步地,聚己内酯溶液与黄原胶溶液的混合体积比为1~2:1~2,黄连素加入后的溶液中黄连素的终浓度为2~10wt%。
进一步地,将纺丝液注入注射器中,调解纺丝参数为:电压15kV、距离20cm、进样速率为1mL/h,经静电纺丝技术制得聚合物溶液后,制备纳米纤维膜;
本发明还提供了一种采用上述制备方法制备得到的聚己内酯-黄原胶-黄连素复合生物膜。
进一步地,黄原胶的质量占复合生物膜的15~25wt%,黄连素的质量占复合生物膜的2~10wt%。
本发明还提供了上述聚己内酯-黄原胶-黄连素复合生物膜在食品医药包装、组织工程和医用敷料领域中的应用。
综上所述,本发明具有以下优点:
1、在静电纺丝过程中添加天然抗菌剂BR,能与黄原胶起到协同抗菌作用,充分发挥BR的药用功效,制备出与人体相容、抗菌效果好的的医用敷料。在静电纺丝过程中与聚己内酯(PCL)共混可以提高力学性能,并添加抗菌物质以增强抗菌性能,抑制伤口的恶化。PCL具有良好的生物相容性以及力学性能,可生物降解,可作为改性剂增强黄原胶的可纺性以及力学性能。
本发明制得的聚己内酯-黄原胶-黄连素复合生物膜,其热稳定性及机械强度高,塑性增强,易碎性及脆性降低,抗菌活性增强,可以广泛应用于食品医药包装、组织工程和医用敷料等领域。
2、本发明制备的聚己内酯-黄原胶-黄连素复合生物膜,其制备过程简单,成本低廉,制得的薄膜材料延展性好,可降解,物理稳定性和化学稳定性好。
3、本发明制备方法将黄原胶与聚己内酯共纺,经过改性后的薄膜均匀,柔韧性好。
附图说明
图1为实施例1-4及不添加黄连素所制备的生物薄膜材料的拉伸应力应变曲线;
图2为添加不同质量分数黄原胶的PCL/XG/BR复合生物膜的形貌图;
图3为添加不同质量分数黄连素的PCL/XG/BR复合生物膜对大肠杆菌的抑菌曲线;
图4为添加不同质量分数黄连素的PCL/XG/BR复合生物膜对枯草芽孢杆菌的抗菌曲线;
图5为添加不同质量分数黄连素的PCL/XG/BR复合生物膜对大肠杆菌的抑菌圈示意图;
图6为添加不同质量分数黄连素的PCL/XG/BR复合生物膜对枯草芽孢杆菌的抑菌圈示意图。
具体实施方式
本发明中的黄原胶的浓度低于10%时,由于黄原胶是具有亲水性,导致膜的通透性较高;成膜时容易产生裂纹甚至孔洞,致使膜的拉伸强度、断裂伸长率下降,水蒸气通过性增加。当黄原胶的浓度大于25%时,随着黄原胶的增加,复合膜粗糙度逐渐增大,表面出现了明显的褶皱,结构变得松散并有可能会给复合膜的机械性能带来损失,复合膜的成型性逐渐变差。
本发明中的黄连素的浓度为2-8wt%时,膜的机械强度、柔韧性及抗菌效果最好。
以下结合实施例对本发明的原理和特征进行描述,所举实例只用于解释本发明,并非用于限定本发明的范围。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
实施例1
本实施例提供了一种聚己内酯-黄原胶-黄连素复合生物膜的制备方法,包括以下步骤:
(1)将10g聚己内酯溶于100mL冰醋酸中;
(2)将50g黄原胶(XG)在80℃,转速为250rpm,机械搅拌下溶于100mL去离子水中,待溶解完全后冷却至室温;
(3)取质量分数为10%的PCL溶液100mL和质量分数为50%的XG溶液100mL于80℃,转速为300rpm,机械搅拌混合均匀,超声脱气后加入黄连素4g,使黄连素的终浓度为2%。80℃,转速为300rpm,搅拌均匀,超声脱气,即得聚己内酯-黄原胶-黄连素纺丝液。
(4)将纺丝溶液注入注射器中,调节纺丝参数为:电压15kV、距离20cm(注射器针尖到接受板间距)、进样速率1mL/h。其中,纺丝温度为20±3℃,相对湿度为60%±5%。制备纳米纤维膜。
实施例2
本实施例提供了一种聚己内酯-黄原胶-黄连素复合生物膜的制备方法,包括以下步骤:
(1)将15g聚己内酯溶于150mL冰醋酸中;
(2)将50g黄原胶(XG)在80℃,转速为400rpm,机械搅拌下溶于100mL去离子水中,待溶解完全后冷却至室温;
(3)取质量分数为10%的PCL溶液150mL和质量分数为50%的XG溶液100mL于80℃,转速为350rpm,机械搅拌混合均匀,超声脱气后加入黄连素10g,使黄连素的终浓度为4%。80℃,转速为350rpm,搅拌均匀,超声脱气,即得聚己内酯-黄原胶-黄连素纺丝液。
(4)将纺丝溶液注入注射器中,调节纺丝参数为:电压15kV、距离20cm(注射器针尖到接受板间距)、进样速率1mL/h。其中,纺丝温度为20±3℃,相对湿度为60%±5%。制备纳米纤维膜。
实施例3
本实施例提供了一种聚己内酯-黄原胶-黄连素复合生物膜的制备方法,包括以下步骤:
(1)将10g聚己内酯溶于100mL冰醋酸中;
(2)将50g黄原胶(XG)在80℃,转速为400rpm,机械搅拌下溶于100mL去离子水中,待溶解完全后冷却至室温;
(3)取质量分数为10%的PCL溶液50mL和质量分数为25%的XG溶液100mL于80℃,转速为450rpm,机械搅拌混合均匀,超声脱气后加入黄连素9g,使黄连素的终浓度为6%。80℃,转速为450rpm,搅拌均匀,超声脱气,即得聚己内酯-黄原胶-黄连素纺丝液。
(4)将纺丝溶液注入注射器中,调节纺丝参数为:电压15kV、距离20cm(注射器针尖到接受板间距)、进样速率1mL/h。其中,纺丝温度为20±3℃,相对湿度为60%±5%。制备纳米纤维膜。
实施例4
本实施例提供了一种聚己内酯-黄原胶-黄连素复合生物膜的制备方法,包括以下步骤:
(1)将10g聚己内酯溶于50mL冰醋酸中;
(2)将25g黄原胶(XG)在80℃,转速为600rpm,机械搅拌下溶于200mL去离子水中,待溶解完全后冷却至室温;
(3)取质量分数为10%的PCL溶液50mL和质量分数为12.5%的XG溶液200mL于80℃,转速为750rpm,机械搅拌混合均匀,超声脱气后加入黄连素20g,使黄连素的终浓度为8%。80℃,转速为750rpm,搅拌均匀,超声脱气,即得聚己内酯-黄原胶-黄连素纺丝液。
(4)将纺丝溶液注入注射器中,调节纺丝参数为:电压15kV、距离20cm(注射器针尖到接受板间距)、进样速率1mL/h。其中,纺丝温度为20±3℃,相对湿度为60%±5%。制备纳米纤维膜。
实施例1-4中所用原料的用量表
对实施例1-4制备的聚己内酯-黄原胶-黄连素复合生物膜进行性能测试,具体过程及结果如下:
1、复合生物膜材料的拉伸应力
依据国标GB-T1040.3 2006中的标准测试方法对实施例1-4所制备的薄膜材料进行拉伸强度(TS)测试,其拉伸应力应变曲线如图1所示。其中1表示实施例1(BR的添加量为聚己内酯-黄原胶-黄连素纺丝液总质量的2%);2表示实施例2(BR的添加量为聚己内酯-黄原胶-黄连素纺丝液总质量的4%);3表示实施例3(BR的添加量为聚己内酯-黄原胶-黄连素纺丝液总质量的6%);4表示实施例4(BR的添加量为聚己内酯-黄原胶-黄连素纺丝液总质量的8%)。
从图1中可以看出,本发明实施例1-4制备出的复合薄膜材料的拉伸应力明显高于对比例(不添加BR),说明黄连素的添加能明显增强复合薄膜材料的拉伸应力。同时,实施例3制备的薄膜材料的拉伸应力明显优于其他实施例,说明当黄连素的添加量为聚己内酯-黄原胶-黄连素纺丝液总质量的6%时能使制备的薄膜材料的拉伸强度达到最大,为78MPa。随着BR质量分数的增加,纤维直径呈现先增大后减小的趋势,且纤维不匀率逐渐增加,添加质量分数为8%的BR时,纤维直径最小,直径不匀率最高。这可归因于BR质量分数较小时,能很好地包覆于PCL/XG中,导致纤维直径增加,而随着纺丝液中BR的继续添加,超过了纤维本身的容纳量,过量的BR会使纺丝液的导电性增强,从而增大了射流在场中的电场力,最终导致纤维被抽长拉细,直径不匀率增加。
2、添加不同质量分数黄原胶的PCL/XG/BR纳米纤维膜的形貌
添加不同质量分数黄原胶的PCL/XG/BR纳米纤维膜(复合生物膜)的形貌(×8000)如图2所示。
图2中,A:含黄原胶质量分数10%的PCL/XG/BR纳米纤维膜表面形貌;B:含黄原胶质量分数20%的PCL/XG/BR纳米纤维膜表面形貌;C:含黄原胶质量分数25%的PCL/XG/BR纳米纤维膜表面形貌。
可以看出,添加质量分数为10%的XG时,膜的通透性较高,纤维的形成的孔洞较多。当添加质量分数为20%的BR时,纤维直径最小,但是当添加XG质量分数为25%时,纤维被拉细拉长,膜的机械性能较差,拉伸强度降低。
3、基于光密度(OD)的PCL/XG/BR薄膜对大肠杆菌和枯草芽孢杆菌的抗菌功能
基于光密度(OD)的聚己内酯-黄原胶-黄连素复合生物膜对大肠杆菌的抗菌功能测试,大肠杆菌生长曲线如图3所示。从图3中可以看出,本发明实施例1制备的聚己内酯-黄原胶-黄连素复合生物膜(参照GB/T20944.3—2008《纺织品抗菌性能的评价,第3部分:振荡法》处理,大小5mm*5mm)对大肠杆菌的抑菌作用,在含有黄连素质量分数为2%-10%均有抑菌作用,而且随着浓度的增加而增加。其中在黄连素质量分数8%时抑菌作用更加显著。而在浓度为8%相比较浓度为10%其抑菌作用增加不明显,说明聚己内酯-黄原胶-黄连素复合生物膜对革兰氏阴性菌大肠杆菌的抗菌功能在8%具有最好效果。
基于光密度(OD)的聚己内酯-黄原胶-黄连素薄膜对枯草芽孢杆菌的抗菌功能测试,枯草芽孢杆菌生长曲线如图4所示。从图4中可以看出,本发明制备的聚己内酯-黄原胶-黄连素复合生物膜对枯草芽孢杆菌在2%-8%浓度有抑菌作用,而且随着浓度的增加而增加。说明聚己内酯-黄原胶-黄连素复合生物膜在含有黄连素质量分数为8%对革兰氏阴性菌枯草芽孢杆菌的抗菌功能具有最好效果。
4、基于涂布平板法的的聚己内酯-黄原胶-黄连素复合生物膜对大肠杆菌的抗菌功能
基于涂布平板法的聚己内酯-黄原胶-黄连素复合生物膜对大肠杆菌的抗菌功能如下图5,从图5中可以看出,图5A是阳性对照,庆大霉素2mg/mL加入涂布大肠杆菌生长的平板上,对大肠杆菌起到完全杀菌作用;图5B是阴性对照,涂布大肠杆菌的平板未加任何抗菌物质;图5C,5D,5E,5F在涂布大肠杆菌的平板上分别加入了黄连素质量分数为2%、4%、6%、8%和10%的PCL/XG/BR薄膜(参照GB/T20944.3—2008《纺织品抗菌性能的评价,第3部分:振荡法》处理,大小5mm*5mm),显示均有明显的抑菌效应,而且随着BR浓度的增加,菌落数量明显减少。
5、基于涂布平板法的聚己内酯-黄原胶-黄连素复合生物膜对枯草芽孢杆菌的抗菌功能
基于涂布平板法的聚己内酯-黄原胶-黄连素复合生物膜对枯草芽孢杆菌的抗菌功能如图6,从图6中可以看出,图6A是阴性对照,涂布枯草芽孢杆菌的平板未加任何抗菌物质;图6B,6C,6D在涂布枯草芽孢杆菌的平板上分别加入了黄连素质量分数为2%,6%,8%的PCL/XG/BR薄膜(参照GB/T20944.3—2008《纺织品抗菌性能的评价,第3部分:振荡法》处理,大小5mm*5mm),显示均有明显的抑菌效应,而且随着BR浓度的增加,菌落数量明显减少。
对比例1
将实施例4中机械搅拌的温度分别更改为20℃或120℃,其它操作不变,研究反应温度对制备的复合薄膜材料性能的影响。应当申明,其它不在本发明搅拌温度范围内的温度都能达和30℃及100℃相同的效果,在此不做具体列举。
20℃时聚己内酯-黄原胶的溶解度小,因而无法形成稳定的凝胶,材料制备不成功。120℃时由于温度较高影响聚己内酯-黄原胶的结合作用,导致形成的薄膜材料力学性能较差。
对比例2
将实施例4中机械搅拌的转速分别更改为200rpm或1000rpm,其它操作不变,研究搅拌的转速对制备的复合薄膜材料性能的影响。应当申明,其它不在本发明搅拌转速范围内的温度都能达和200rpm或1000rpm相同的效果,在此不做具体列举。
200rpm的转速会导致凝胶形成不均匀,会有少量的结块出现。1000rpm的转速制备的薄膜材料力学性能与实施例中制备的材料相当,没有本质性的差异,但是此转速下会在制备的过程中产生液体飞溅的现象,不利于实验制备控制。
对比例3
将实施例4中自然干燥时间改为12h或48h,其它操作不变,研究干燥温度对制备的复合薄膜材料性能的影响。应当申明,其它不在本发明干燥温度范围内的温度都能达和12h及48h相同的效果,在此不做具体列举。12h或48h的冷冻干燥时间,48h时时间太长,延长制备周期;12h会较实施例缩短,但是制备的薄膜材料会太软,塑性和机械强度不够。
虽然对本发明的具体实施方式进行了详细地描述,但不应理解为对本专利的保护范围的限定。在权利要求书所描述的范围内,本领域技术人员不经创造性劳动即可作出的各种修改和变形仍属本专利的保护范围。
Claims (7)
1.一种聚己内酯-黄原胶-黄连素复合生物膜的制备方法,其特征在于,包括以下步骤:
将聚己内酯溶液与黄原胶溶液混合均匀后,超声脱气并加入黄连素,搅拌并超声脱气后,制得聚己内酯-黄原胶-黄连素纺丝液;
将纺丝液注入注射器中,调解纺丝参数为:电压15kV、距离20cm、进样速率为1mL/h,经静电纺丝技术制得纳米纤维膜;
所述静电纺丝的纺丝温度为17~23℃,所述静电纺丝的相对湿度为55~65%,所述静电纺丝的时间为24~48h。
2.如权利要求1所述的制备方法,其特征在于,所述聚己内酯溶液由聚己内酯溶解于冰醋酸溶液中制得,所述聚己内酯溶液中聚己内酯的质量分数为8~12wt%。
3.如权利要求1所述的制备方法,其特征在于,所述黄原胶溶液由黄原胶溶解于去离子水中制得,所述黄原胶溶液中黄原胶的浓度为0.15~0.18g/mL,所述溶解的温度为75~85℃。
4.如权利要求1所述的制备方法,其特征在于,所述聚己内酯溶液与黄原胶溶液的混合体积比为1~2:1~2,所述黄连素加入后的溶液中黄连素的终浓度为2~10wt%。
5.采用权利要求1-4任一项所述的制备方法制备得到的聚己内酯-黄原胶-黄连素复合生物纤维膜。
6.如权利要求5所述的聚己内酯-黄原胶-黄连素复合生物膜,其特征在于,所述黄原胶的质量占复合生物膜的15~25wt%,所述黄连素的质量占复合生物膜的2~10wt%。
7.如权利要求5或6所述的聚己内酯-黄原胶-黄连素复合生物膜在食品医药包装、组织工程和医用敷料领域中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210815912.9A CN115212338A (zh) | 2022-07-12 | 2022-07-12 | 一种聚己内酯-黄原胶-黄连素复合生物膜及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210815912.9A CN115212338A (zh) | 2022-07-12 | 2022-07-12 | 一种聚己内酯-黄原胶-黄连素复合生物膜及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115212338A true CN115212338A (zh) | 2022-10-21 |
Family
ID=83611275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210815912.9A Pending CN115212338A (zh) | 2022-07-12 | 2022-07-12 | 一种聚己内酯-黄原胶-黄连素复合生物膜及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115212338A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101804218A (zh) * | 2010-04-13 | 2010-08-18 | 王艳 | 含有云南白药或者云南白药提取物的人体可吸收外伤敷料 |
US20160038611A1 (en) * | 2013-03-12 | 2016-02-11 | Active Fibres Limited | Nanofibre and Bioactive Compositions and Related Methods |
CN105854068A (zh) * | 2015-01-21 | 2016-08-17 | 天津开发区金衫包装制品有限公司 | 一种含中药抗菌成分黄连素的海藻酸钠纳米纤维医用敷料及其制备方法 |
CN107519524A (zh) * | 2017-09-21 | 2017-12-29 | 滨州医学院 | 一种聚己内酯/胶原蛋白/季铵盐静电纺丝复合纤维膜及其制备方法 |
WO2019038430A1 (en) * | 2017-08-25 | 2019-02-28 | Eleonor Sprl | COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERIN ALKALOID AND METHOD FOR PRODUCING THE SAME |
CN109487439A (zh) * | 2018-11-15 | 2019-03-19 | 无锡中科光远生物材料有限公司 | 一种黄原胶/壳聚糖纳米纤维膜的制备方法 |
CN112494463A (zh) * | 2020-11-23 | 2021-03-16 | 潍坊医学院 | 一种小檗碱/矿化胶原复合膜及其制备方法和应用 |
-
2022
- 2022-07-12 CN CN202210815912.9A patent/CN115212338A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101804218A (zh) * | 2010-04-13 | 2010-08-18 | 王艳 | 含有云南白药或者云南白药提取物的人体可吸收外伤敷料 |
US20160038611A1 (en) * | 2013-03-12 | 2016-02-11 | Active Fibres Limited | Nanofibre and Bioactive Compositions and Related Methods |
CN105854068A (zh) * | 2015-01-21 | 2016-08-17 | 天津开发区金衫包装制品有限公司 | 一种含中药抗菌成分黄连素的海藻酸钠纳米纤维医用敷料及其制备方法 |
WO2019038430A1 (en) * | 2017-08-25 | 2019-02-28 | Eleonor Sprl | COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERIN ALKALOID AND METHOD FOR PRODUCING THE SAME |
CN107519524A (zh) * | 2017-09-21 | 2017-12-29 | 滨州医学院 | 一种聚己内酯/胶原蛋白/季铵盐静电纺丝复合纤维膜及其制备方法 |
CN109487439A (zh) * | 2018-11-15 | 2019-03-19 | 无锡中科光远生物材料有限公司 | 一种黄原胶/壳聚糖纳米纤维膜的制备方法 |
CN112494463A (zh) * | 2020-11-23 | 2021-03-16 | 潍坊医学院 | 一种小檗碱/矿化胶原复合膜及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
莫秀梅: "《天然活性物质在饲料中的应用研究及策略》", vol. 1, 中国农业大学出版社, pages: 42 - 43 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ambekar et al. | Advancements in nanofibers for wound dressing: A review | |
Bakhsheshi-Rad et al. | Development of the PVA/CS nanofibers containing silk protein sericin as a wound dressing: In vitro and in vivo assessment | |
Mehrabani et al. | Chitin/silk fibroin/TiO2 bio-nanocomposite as a biocompatible wound dressing bandage with strong antimicrobial activity | |
RU2468129C2 (ru) | Биополимерное волокно, состав формовочного раствора для его получения, способ приготовления формовочного раствора, полотно биомедицинского назначения, способ его модификации, биологическая повязка и способ лечения ран | |
Gao et al. | Antibacterial and hemostatic bilayered electrospun nanofibrous wound dressings based on quaternized silicone and quaternized chitosan for wound healing | |
Wei et al. | The multifunctional wound dressing with core–shell structured fibers prepared by coaxial electrospinning | |
RU2487701C2 (ru) | Раствор для получения материала на основе хитозана, способ получения гемостатического материала из этого раствора (варианты) и медицинское изделие с использованием волокон на основе хитозана | |
TW200925342A (en) | Method for production of nanofibres | |
CN103194856B (zh) | 抗菌、伤口愈合作用的壳聚糖/丝胶复合纳米纤维的制备方法 | |
Xie et al. | Functionalized biomimetic composite nanfibrous scaffolds with antibacterial and hemostatic efficacy for facilitating wound healing | |
Felgueiras et al. | Biodegradable, spun nanocomposite polymeric fibrous dressings loaded with bioactive biomolecules for an effective wound healing: A review | |
CN106110383A (zh) | 一种壳聚糖藻酸盐敷料及其冻干制备方法 | |
Preem et al. | Electrospun antimicrobial wound dressings: Novel strategies to fight against wound infections | |
CN110152049B (zh) | 一种医用伤口敷料的壳聚糖基纳米纤维膜的应用 | |
Kharat et al. | Herbal extract loaded chitosan/PEO nanocomposites as antibacterial coatings of orthopaedic implants | |
Lan et al. | Preparation and characterization of silk fibroin/polyethylene oxide nanofiber membranes with antibacterial activity | |
Yang et al. | A facile, biosynthetic design strategy for high-performance multifunctional bacterial cellulose-based dressing | |
CN113846423B (zh) | 一种生物全降解复合纤维膜的制备方法 | |
Li et al. | Sandwich structure Aloin-PVP/Aloin-PVP-PLA/PLA as a wound dressing to accelerate wound healing | |
Vega-Cázarez et al. | Overview of electrospinned chitosan nanofiber composites for wound dressings | |
Manotham et al. | Electrospun biopolymer polyvinyl alcohol/Centella asiatica extract nanofibers for antibacterial activity | |
Davis et al. | Passive and interactive dressing materials | |
Ran et al. | Fabrication of antimicrobial poly (lactic‐co‐glycolic acid)/silk fibroin/aloe anthraquinone fibrous membranes for potential application of wound healing | |
CN115212338A (zh) | 一种聚己内酯-黄原胶-黄连素复合生物膜及其制备方法与应用 | |
CN116407674A (zh) | 一种载有单宁酸的高强度可自愈抗菌水凝胶的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221021 |